Salute e Benessere
Cardiovalve Completes TARGET Study Enrollment for CE Registration Study for Tricuspid Valve Replacement
With enrollment now complete, the company is preparing to submit its to European regulators later this year. Pending approval, .
Building on this achievement, Cardiovalve is also preparing to initiate its , which will evaluate the safety and performance of Cardiovalve's in patients suffering from significant mitral regurgitation (MR). The AHEAD study is designed to support a future for the mitral system.
Cardiovalve will present preliminary data for its mitral regurgitation (MR) system at .
The presentation, titled "Transcatheter Mitral Valve Replacement Using the New Generation Cardiovalve System," will be led by
:
A subsidiary of , is a pioneer in transcatheter valve replacement technology, standing at the forefront of innovation in structural heart therapy. With more than , a highly experienced team, and a , Cardiovalve is dedicated to providing physicians with next-generation solutions that improve patient outcomes and quality of life—without the need for open-heart surgery.
is a leading innovator in transcatheter heart valve solutions for structural heart disease. The company has developed a comprehensive product pipeline covering all four heart valves — —and related accessory products. With global R&D centers in China , the United States , and Israel , The company is committed to providing effective treatment solutions for life-threatening diseases.
View original content:https://www.prnewswire.co.uk/news-releases/cardiovalve-completes-target-study-enrollment-for-ce-registration-study-for-tricuspid-valve-replacement-302593469.html